Grant Award Details

An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology
Grant Number: 
DISC1-10079
Project Objective: 
  • This project will determine the effectiveness of a potentially transformational stem cell based therapy—human stem cell derived exosomes—to ameliorate the neuropathologies associated with AD.


Investigator: 
Type: 
PI
Disease Focus: 
Alzheimer's Disease
Neurological Disorders
Human Stem Cell Use: 
Embryonic Stem Cell
Award Value: 
$157,650
Status: 
Closed

Progress Reports

Reporting Period: 
Year 1

Grant Application Details

Application Title: 
  • An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology
Public Abstract: 

Research Objective

These studies will determine whether stem cell derived exosomes (nano-scale vesicles) can be used to treat the symptoms of Alzheimer’s disease (AD).

Impact

Our stem cell-derived exosome therapy will provide a viable approach to ameliorate the relentless progression of AD that severely impacts quality of life for millions of patients and their families.

Major Proposed Activities

  • Evaluate whether exosome therapy can reduce the symptoms of early stage AD including anxiety, depression, and learning and memory.
  • Evaluate whether exosome therapy can reduce the symptoms of advanced stage AD including anxiety, depression, and learning and memory.
  • Determine whether exosome therapy can slow the appearance of AD related changes typically observed in the early stage AD brain.
  • Determine whether exosome therapy can reduce the appearance of AD related changes typically observed in the advanced stage AD brain.
Statement of Benefit to California: 

In the US, California has the most cases of AD, a burden on patients, their families, and the health care system. As such, AD is an unmet medical need that requires new therapies to improve disease management. This project tests a transformational idea—human stem cell derived exosome therapy. These studies will identify a novel stem cell-based strategy and a viable approach to impede the progression of AD and it’s symptoms that severely impact quality of life for patients and their families.